Sitagliptin and aprepitant launched in Japan
This article was originally published in Scrip
Executive Summary
Two Merck & Co products, Januvia (sitagliptin) for diabetes and Emend (aprepitant) for chemotherapy-induced nausea and vomiting, have been launched in Japan, on the day of their reimbursement price listing on December 11th.